Same Pill, Different Hearts: How AI Made Bioinformatics Medicine's Most Powerful Field

Picture two men in neighbouring beds in a Mumbai cardiac ward. Both have just had a stent placed in a blocked artery. Both are handed the same small white tablet, clopidogrel, to stop a dangerous clot from forming.

For one of them, the drug works perfectly. For the other, it barely works at all.

The difference is not his diet, his age, or his doctor. It is a single gene called CYP2C19, which the liver uses to switch clopidogrel on. Some versions of this gene are sluggish, and they are strikingly common in India. A study of heart attack patients at Government Medical College, Thrissur found the variant in 62 percent of them. Another study at Army Hospital, Delhi found that 52 percent of stent patients activated the drug poorly.

Same pill. Different genes. Reading those genes at scale is the job of bioinformatics.

A Subject I Studied Before Its Time

I studied bioinformatics in college. Back then it felt like a quiet niche, a meeting point for biologists who liked computers and engineers who liked biology. The tools were slow, the datasets were small and the work stayed inside the lab.

That has changed completely. Artificial intelligence has turned bioinformatics from a back-room specialty into one of the most important fields in modern medicine.

At its core, the idea is simple:

Biology + Computer Science + Statistics = Bioinformatics

Your genome is roughly 3 billion letters of DNA, written in just four chemical bases: A, T, G and C. Bioinformatics is the science of storing, searching, and making sense of that code, then connecting it to disease, drugs, and treatment.

From $2.7 Billion to $200

The Human Genome Project, completed in 2003, took 13 years and an estimated 2.7 billion dollars to produce the first human genome. In 2022, Illumina, the world's largest sequencing company, unveiled its NovaSeq X machines with a target of just 200 dollars per genome.

When reading DNA becomes that cheap, the hard part is no longer generating data. It is understanding it, across millions of patients, at a scale no human team can manage. That is where AI walked in.

The Nobel Prize That Announced a New Era

In October 2024, the Nobel Prize in Chemistry went to Demis Hassabis and John Jumper of Google DeepMind for AlphaFold, an AI system that predicts the 3D shape of a protein from its sequence. They shared it with David Baker of the University of Washington, honoured for computational protein design.

Working out one protein's structure once took years of lab work using X-ray crystallography. AlphaFold has now predicted the structures of virtually all 200 million proteins known to science, and has been used by more than 2 million people in 190 countries.

For bioinformatics, it was a coronation.

India Is Reading Its Own Code

In January 2025, India released genome data from 10,000 citizens under the GenomeIndia Project, drawn from 85 population groups. The data sits at the Indian Biological Data Centre in Faridabad, and the government has announced a target of 10 million genomes.

Most global genetic databases are built on European populations. An earlier CSIR programme, IndiGen, sequenced 1,029 Indians and found that about 32 percent of their genetic variants were unique to Indian genomes. Medicine designed around someone else's DNA will not always work for ours, as the clopidogrel story shows.

In October 2023, NexCAR19, developed by IIT Bombay spin-off ImmunoACT with Tata Memorial Centre, became India's first approved CAR-T cell therapy for blood cancers. Imported versions cost around 400,000 dollars. NexCAR19 launched at roughly Rs 30 to 40 lakh.

Six Medical Frontiers Running on Bioinformatics

Personalised and genetic medicine are just the start. Each of these fields depends on people who can read biological data:

1. Personalised Medicine: treatment chosen for your genetic profile, not the average patient.

2. Pharmacogenomics: predicting how your genes will respond to a drug, as with clopidogrel.

3. Gene and Cell Therapy: editing or reprogramming cells to fix disease at its source, as CAR-T does.

4. Precision Oncology: sequencing a tumour to find the exact mutation driving it, and the drug that targets it.

5. Proteomics and Structural Biology: mapping proteins, the molecular machines that drugs actually bind to.

6. Rare Disease Diagnosis: reading a child's whole genome to end years of searching for answers.

The Careers Being Written Right Now

The global bioinformatics services market is projected to grow from 4.2 billion dollars in 2025 to 11.5 billion dollars by 2032, with Asia Pacific, led by China and India, the fastest-growing region. India's own bioinformatics market reached about 577 million dollars in 2025.

The job titles barely existed a generation ago: computational biologist, clinical genomics analyst, bioinformatics engineer, AI drug discovery scientist. They share a hybrid skill set. A biology student who learns Python, or a computer science student who learns genetics, will find doors open that stay closed to others.

How Futurowise Can Help

Bioinformatics is, at its heart, data science applied to life itself. At Futurowise, our Foundations of Data Science programme teaches students to work with real datasets, think in patterns, and build a real project of their own. It is the same toolkit behind genome analysis and AI drug discovery. The students who understand how biological data works today will be the ones designing the medicines of tomorrow.

Learn more about the programme: https://www.futurowise.com/programs/foundations-of-data-science